A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).
Martín M, Chan A, Dirix L, O'Shaughnessy J, Hegg R, Manikhas A, Shtivelband M, Krivorotko P, Batista López N, Campone M, Ruiz Borrego M, Khan QJ, Beck JT, Ramos Vázquez M, Urban P, Goteti S, Di Tomaso E, Massacesi C, Delaloge S.
Martín M, et al. Among authors: urban p.
Ann Oncol. 2017 Feb 1;28(2):313-320. doi: 10.1093/annonc/mdw562.
Ann Oncol. 2017.
PMID: 27803006
Free article.
Clinical Trial.